NASDAQ:PLXP - PLx Pharma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.69 +0.09 (+2.50 %) (As of 10/19/2018 04:00 PM ET)Previous Close$3.69Today's Range$3.62 - $3.702252-Week Range$3.05 - $9.40Volume403 shsAverage Volume5,755 shsMarket Capitalization$31.45 millionP/E Ratio-1.89Dividend YieldN/ABeta1.75 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email PLx Pharma Inc., a late-stage specialty pharmaceutical company, focuses on developing non-steroidal anti-inflammatory drugs (NSAIDs) and other analgesics. The company's lead product candidates are Aspertec 81 mg and 325 mg, which are novel formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention. Its product pipeline also includes other oral NSAIDs using the PLxGuard delivery system, including PL1200 Ibuprofen 200 mg, a clinical-stage GI-safer ibuprofen product for pain and inflammation. The company was founded in 2002 and is headquartered in Houston, Texas. Receive PLXP News and Ratings via Email Sign-up to receive the latest news and ratings for PLXP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:PLXP CUSIPN/A Webwww.plxpharma.com Phone713-842-1249 Debt Debt-to-Equity Ratio0.93 Current Ratio9.15 Quick Ratio9.15 Price-To-Earnings Trailing P/E Ratio-1.89 Forward P/E Ratio-2.48 P/E GrowthN/A Sales & Book Value Annual Sales$780,000.00 Price / Sales41.35 Cash FlowN/A Price / CashN/A Book Value$0.53 per share Price / Book6.96 Profitability EPS (Most Recent Fiscal Year)($1.95) Net Income$-15,340,000.00 Net Margins-12.57% Return on Equity-169.28% Return on Assets-49.51% Miscellaneous Employees14 Outstanding Shares8,740,000Market Cap$31.45 million PLx Pharma (NASDAQ:PLXP) Frequently Asked Questions What is PLx Pharma's stock symbol? PLx Pharma trades on the NASDAQ under the ticker symbol "PLXP." How were PLx Pharma's earnings last quarter? PLx Pharma Inc (NASDAQ:PLXP) posted its quarterly earnings results on Friday, August, 10th. The biotechnology company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.11. The biotechnology company earned $0.17 million during the quarter. PLx Pharma had a negative net margin of 12.57% and a negative return on equity of 169.28%. View PLx Pharma's Earnings History. When is PLx Pharma's next earnings date? PLx Pharma is scheduled to release their next quarterly earnings announcement on Thursday, November 8th 2018. View Earnings Estimates for PLx Pharma. What price target have analysts set for PLXP? 1 equities research analysts have issued twelve-month price targets for PLx Pharma's shares. Their forecasts range from $14.00 to $14.00. On average, they anticipate PLx Pharma's stock price to reach $14.00 in the next year. This suggests a possible upside of 279.4% from the stock's current price. View Analyst Price Targets for PLx Pharma. What is the consensus analysts' recommendation for PLx Pharma? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PLx Pharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PLx Pharma. Who are some of PLx Pharma's key competitors? Some companies that are related to PLx Pharma include MOTIF BIO PLC/S (MTFB), Sol Gel Technologies (SLGL), Neos Therapeutics (NEOS), Correvio Pharma (CORV), Catalyst Biosciences (CBIO), vTv Therapeutics (VTVT), CTI BioPharma (CTIC), XOMA (XOMA), Provention Bio (PRVB), TapImmune (TPIV), Axsome Therapeutics (AXSM), Aerpio Pharmaceuticals (ARPO), Oncolytics Biotech (ONCYF), Oncomed Pharmaceuticals (OMED) and Aridis Pharmaceuticals (ARDS). Who are PLx Pharma's key executives? PLx Pharma's management team includes the folowing people: Mr. Michael J. Valentino, Exec. Chairman (Age 64)Ms. Natasha Giordano, Chief Exec. Officer, Pres and Director (Age 58)Mr. Gary L. Mossman, Sr. Advisor (Age 77)Mr. Ronald R. Zimmerman, Founder and Sr. Advisor (Age 65)Ms. Rita M. O'Connor CPA, Chief Financial Officer (Age 50) When did PLx Pharma IPO? (PLXP) raised $68 million in an initial public offering (IPO) on Thursday, February 4th 2016. The company issued 3,800,000 shares at $17.00-$19.00 per share. Raymond James acted as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers. How do I buy shares of PLx Pharma? Shares of PLXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is PLx Pharma's stock price today? One share of PLXP stock can currently be purchased for approximately $3.69. How big of a company is PLx Pharma? PLx Pharma has a market capitalization of $31.45 million and generates $780,000.00 in revenue each year. The biotechnology company earns $-15,340,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. PLx Pharma employs 14 workers across the globe. What is PLx Pharma's official website? The official website for PLx Pharma is http://www.plxpharma.com. How can I contact PLx Pharma? PLx Pharma's mailing address is 8285 EL RIO STREET SUITE 130, HOUSTON TX, 77054. The biotechnology company can be reached via phone at 713-842-1249 or via email at [email protected] MarketBeat Community Rating for PLx Pharma (NASDAQ PLXP)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 105 (Vote Outperform)Underperform Votes: 134 (Vote Underperform)Total Votes: 239MarketBeat's community ratings are surveys of what our community members think about PLx Pharma and other stocks. Vote "Outperform" if you believe PLXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLXP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/20/2018 by MarketBeat.com StaffFeatured Article: What is the NASDAQ?